



## King's Research Portal

DOI:

[10.1177/2045125319881916](https://doi.org/10.1177/2045125319881916)

*Document Version*

Publisher's PDF, also known as Version of record

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Davies, C., & Bhattacharyya, S. (2019). Cannabidiol as a Potential Treatment for Psychosis. *Therapeutic Advances in Psychopharmacology*. <https://doi.org/10.1177/2045125319881916>

### **Citing this paper**

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### **General rights**

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### **Take down policy**

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

# Cannabidiol as a potential treatment for psychosis

Cathy Davies<sup>ID</sup> and Sagnik Bhattacharyya

*Ther Adv Psychopharmacol*

2019, Vol. 9: 1–16

DOI: 10.1177/  
2045125319881916

© The Author(s), 2019.  
Article reuse guidelines:  
sagepub.com/journals-  
permissions

**Abstract:** Psychotic disorders such as schizophrenia are heterogeneous and often debilitating conditions that contribute substantially to the global burden of disease. The introduction of dopamine D2 receptor antagonists in the 1950s revolutionised the treatment of psychotic disorders and they remain the mainstay of our treatment arsenal for psychosis. However, traditional antipsychotics are associated with a number of side effects and a significant proportion of patients do not achieve an adequate remission of symptoms. There is therefore a need for novel interventions, particularly those with a non-D2 antagonist mechanism of action. Cannabidiol (CBD), a non-intoxicating constituent of the cannabis plant, has emerged as a potential novel class of antipsychotic with a unique mechanism of action. In this review, we set out the prospects of CBD as a potential novel treatment for psychotic disorders. We first review the evidence from the perspective of preclinical work and human experimental and neuroimaging studies. We then synthesise the current evidence regarding the clinical efficacy of CBD in terms of positive, negative and cognitive symptoms, safety and tolerability, and potential mechanisms by which CBD may have antipsychotic effects.

**Keywords:** antipsychotics, cannabidiol, cannabinoids, cannabis, psychosis, schizophrenia, treatment

Received: 12 July 2019; revised manuscript accepted: 19 September 2019.

## Introduction

Psychotic disorders such as schizophrenia are heterogeneous and often debilitating conditions that contribute substantially to the global burden of disease.<sup>1</sup> Patients with psychosis present with a range of psychopathology across positive, negative and cognitive symptom domains. The introduction of dopamine (primarily D2) receptor antagonists in the 1950s revolutionised the treatment of psychotic disorders and they remain the mainstay of our treatment arsenal for psychosis.<sup>2</sup> However, a significant proportion of patients either do not respond to traditional antipsychotics or do not achieve a complete or adequate remission of symptoms.<sup>3</sup> In addition, most current antipsychotics only target the positive symptoms of psychosis, with little effect on negative or cognitive symptoms.<sup>2</sup> Dopamine-acting antipsychotics are also associated with a number of side effects,<sup>4</sup> some of which can be severe and which may contribute to nonadherence. There is therefore a need

for novel interventions, particularly those with a non-D2 antagonist mechanism of action, and which may thereby avoid some of the adverse effects of modulating the dopamine system directly. In line with this, over recent years there has been increasing interest in the development of treatments with alternate mechanisms of action.<sup>5</sup>

Accumulating evidence implicates the endocannabinoid system in the pathophysiology of psychosis.<sup>6,7</sup> A recent meta-analysis concluded that patients with psychosis have significantly higher levels of the endocannabinoid anandamide both in cerebrospinal fluid and in blood, and higher expression of the main central cannabinoid 1 receptor (CB1) on peripheral immune cells.<sup>8</sup> This elevated endocannabinoid tone was observed at all stages of illness, from the prodrome to chronic psychosis.<sup>8</sup> Alterations in CB1 receptor expression have also been observed in postmortem tissue and *in vivo* in patients with psychosis.<sup>9–11</sup>

Correspondence to:  
**Sagnik Bhattacharyya**  
Department of Psychosis  
Studies, 6th Floor, Institute  
of Psychiatry, Psychology  
& Neuroscience, King's  
College London, 16 De  
Crespigny Park, London,  
SE5 8AF, UK  
[sagnik.2.bhattacharyya@kcl.ac.uk](mailto:sagnik.2.bhattacharyya@kcl.ac.uk)

**Cathy Davies**  
Department of Psychosis  
Studies, Institute of  
Psychiatry, Psychology  
& Neuroscience, King's  
College London, London,  
UK

If the endocannabinoid system plays a role in psychosis pathophysiology, it raises the interesting possibility that pharmacological compounds that modulate this system may have therapeutic value.

Cannabidiol (CBD), a phytocannabinoid constituent of *Cannabis sativa*, has been heralded as one such potential treatment. While the main psychoactive ingredient in cannabis, delta-9-tetrahydrocannabinol (THC), has anxiogenic, psychotomimetic and amnestic effects, CBD is non-intoxicating and has potential anxiolytic, antipsychotic and anticonvulsant properties, and no detrimental effects on memory.<sup>12</sup> Epidemiological findings support these opposing effect profiles; extensive evidence implicates cannabis use as a risk factor for the development of psychosis and poor outcomes in cannabis-using patients.<sup>13,14-19</sup> However, the adverse effects of cannabis use on the risk of onset and subsequent outcome in psychosis are particularly evident in those using high potency skunk-like cannabis (i.e. with high levels of THC and low levels of CBD) as opposed to those using hash-like cannabis (i.e. with lower THC and higher CBD).<sup>15,20-22</sup> This pattern of findings is consistent with evidence that CBD not only has opposing effects to THC but may also block some of its adverse (and particularly psychotomimetic) effects.<sup>23,24</sup>

Importantly, CBD has a different mechanism of action to dopamine receptor antagonists and could therefore represent a completely novel class of antipsychotic treatment.<sup>25</sup> This would be associated with numerous benefits. First, by avoiding dopamine receptor antagonism, adverse effects such as extrapyramidal symptoms and increased prolactin may be avoided. Second, if CBD acts *via* different molecular pathways to current antipsychotics, it could be used not only as monotherapy but potentially as an adjunctive treatment alongside existing antipsychotics, with potential complementary gains in efficacy. While CBD is currently being tested in relation to a number of psychiatric disorders and physical health conditions,<sup>12</sup> this review synthesises and summarises the current evidence regarding the therapeutic potential of CBD as a treatment for psychosis.

### Evidence for antipsychotic potential of cannabidiol

The accumulating evidence regarding the antipsychotic potential of CBD has emerged from a number of different sources. This includes preclinical

work, experimental studies in healthy human volunteers comparing the neurocognitive effects of THC and CBD as well as studies examining whether CBD can block or attenuate the symptomatic effects of THC.

#### Preclinical evidence

Indirect evidence for the antipsychotic and anxiolytic effects of CBD comes from preclinical studies, where specific features of psychotic disorders are modelled in animals and allow potential therapeutic effects to be examined from molecular to behavioural levels.<sup>26</sup>

**Hyperlocomotion.** Hyperlocomotion is thought to be a model of positive psychotic symptoms and can be rescued using antipsychotics.<sup>26</sup> CBD has been shown to reduce hyperlocomotion induced by amphetamine (dopamine agonist) and ketamine [N-methyl-D-aspartate (NMDA) receptor antagonist] while at the same time not inducing catalepsy,<sup>27</sup> which suggests that it has antipsychotic-like beneficial effects without the detrimental motor side effects, with a profile resembling that of the atypical antipsychotic clozapine.<sup>28</sup>

**Pre-pulse inhibition deficits.** Pre-pulse inhibition (PPI) deficits represent sensorimotor gating abnormalities, thought to be a stable trait (bio) marker that is present across the psychosis spectrum.<sup>29</sup> Peripubertal CBD has been found to prevent the development of PPI deficits in the spontaneously hypertensive rat strain model,<sup>30</sup> which suggests that CBD may have long-lasting prophylactic effects, while it did not negatively impact PPI in control mice.

**Social withdrawal and cognition.** Methylazoxymethanol treatment induces numerous behavioural and cognitive deficits (social interaction and novel object recognition) as well as a range of pathophysiological manifestations analogous to those in schizophrenia,<sup>31</sup> including altered CB1 expression in prefrontal cortex. Peripubertal CBD reversed the methylazoxymethanol-induced alterations in CB1 expression and the schizophrenia-like phenotype, neither of which are rescued by haloperidol.<sup>32</sup> CBD has been found to reduce social withdrawal induced by THC but not polyinosinic-polycytidylic acid.<sup>33,34</sup> CBD can also attenuate MK-801 (an NMDA receptor antagonist)-induced changes in social behaviours, cognition and expression of various glial markers.<sup>35</sup> These latter findings suggest potential neuroprotective and anti-inflammatory

properties of CBD,<sup>12</sup> which is supported by independent evidence that CBD can promote hippocampal neurogenesis and rescue memory function,<sup>36,37</sup> consistent with human studies showing that CBD attenuates THC-elicited cognitive impairment.<sup>23,38</sup>

#### *Human experimental and neuroimaging studies*

Complementary insight into the antipsychotic potential of CBD has come from neuroimaging studies, which provide a means to noninvasively examine the systems (i.e. neural substrates) on which CBD may act to produce its antipsychotic and anxiolytic effects *in vivo*.

THC and CBD have been shown to have opposite effects on regional brain activation across a variety of cognitive tasks in healthy individuals.<sup>24</sup> Interestingly, this has been found in brain regions where patients with psychosis show dysfunction and during tasks that are known to be impaired by cannabis use. Using a double-blind, placebo-controlled, repeated-measures design, 15 healthy volunteers were studied on three occasions with functional magnetic resonance imaging (fMRI) after receiving a single dose of CBD (600mg), THC (10mg) or placebo.<sup>24</sup> In this series of experiments, THC-induced psychotic symptoms were directly related to the attenuating effects of THC on striatal activation during verbal recall and salience processing,<sup>24,39</sup> suggesting that the psychotogenic effects of THC may be mediated in part by effects on the striatum. In contrast, CBD augmented activation in the same regions during the task and did not induce psychotic symptoms. When viewing fearful faces, THC augmented activation in the amygdala, which was associated with induction of anxiety symptoms and increased physiological anxiety (measured using skin conductance response).<sup>24</sup> Conversely, CBD attenuated amygdala activation and this was significantly associated with the concurrent CBD-induced decrease in physiological anxiety (skin conductance response), suggesting that these effects may account for the anxiolytic properties of CBD. THC and CBD also had directly opposing effects on activation in the hippocampus during response inhibition,<sup>24</sup> the superior temporal cortex when listening to speech,<sup>24</sup> the occipital cortex during visual processing and on functional connectivity within regions processing attentional salience.<sup>24,40</sup>

Further evidence for the protective effects of CBD against the psychotomimetic, anxiogenic,

and cognition-impairing effects of THC comes from experimental studies where the two cannabinoids have been co-administered. THC can be used as an experimental model of psychosis in humans because its acute administration in healthy individuals can induce transient psychotic-like symptoms (including both positive and negative symptoms), as well as cognitive deficits resembling those seen in schizophrenia.<sup>41–47</sup> In one study, six healthy volunteers received intravenous THC (1.25mg) on two occasions, once preceded by intravenous placebo and once by CBD (2.5mg) in a double-blind, within-subject design.<sup>24</sup> At the group level, THC administration with placebo pretreatment was associated with transient psychotomimetic effects, which was not observed under the CBD pretreatment condition.<sup>24</sup> A larger between-group study ( $n=48$ ) showed that relative to placebo, pretreatment with 600mg oral CBD reduced the paranoia and impairments in episodic memory elicited by 1.5mg intravenous THC.<sup>23</sup>

In summary, a growing body of literature suggests that CBD attenuates the pro-psychotic, anxiety and cognitive effects elicited by THC in healthy individuals at both the neurophysiological and behavioural (psychopathological) level. In addition, CBD has opposite effects to THC on regional brain activation and functional connectivity across a range of cognitive tasks (including salience processing, learning and memory, response inhibition and fear processing) in regions known to be disrupted in patients with psychosis.<sup>24,39,40</sup> Together, this accumulating evidence supports a potential therapeutic role for CBD in the treatment of psychosis and is consistent with independent evidence that CBD has antipsychotic effects in patients with the disorder (see below).

#### **Cannabidiol in psychosis: current clinical evidence**

##### *Positive and negative psychotic symptoms*

*Initial studies.* The 1990s saw the first studies investigating the effects of CBD in patients with psychosis. Results from a single ( $n=1$ ) case study of a 19-year-old female with acutely exacerbated schizophrenia reported that oral CBD, titrated up to 1500mg/day over 4 weeks, was associated with a reduction in psychotic symptoms as measured with the Brief Psychiatric Rating Scale (BPRS).<sup>48</sup> A subsequent case series examined the effects of

oral CBD monotherapy (up to 1280 mg/day) for 30 days in three patients with treatment-resistant schizophrenia.<sup>49</sup> Here, one patient showed mild improvement in BPRS scores while two did not, but CBD was well tolerated: there were no side effects reported even up to the maximum dosage.<sup>49</sup> CBD has now been investigated in a number of larger-scale studies including randomised controlled trials (Table 1). The current review was not intended to be a fully systematic review, but to our knowledge, the information regarding previous clinical trials of CBD in psychosis is a complete and accurate record of all relevant studies up to July 2019.

*CBD as monotherapy.* One of the first landmark studies in patients with schizophrenia compared up to 800 mg/day of oral CBD with up to 800 mg/day of the antipsychotic amisulpride. In a randomised, double-blind, parallel-arm trial, 39 patients with an acute exacerbation of schizophrenia symptoms were treated over 4 weeks.<sup>53</sup> By day 28, there was a significant reduction in positive symptoms, as measured using the Positive and Negative Syndrome Scale (PANSS), in both the CBD group (change from baseline to day 28;  $M \pm SD = -9.0 \pm 6.1$ ,  $p < 0.001$ ) and the amisulpride group ( $-8.4 \pm 7.5$ ,  $p < 0.001$ ), with no significant difference in efficacy between the treatments.<sup>53</sup> This pattern of findings emerged also for negative, total and general symptoms, with significant reductions by day 28 in both treatment arms (all change-from-baseline comparisons  $p < 0.001$ ), and no significant between-treatment differences. These findings were the first robust indication that CBD may have antipsychotic efficacy, given the suggestion of noninferiority to the D2/D3 antagonist amisulpride. However, the most striking findings came from the evaluation of side effects. Extrapyramidal symptoms, weight gain and increased prolactin are common side effects of antipsychotics<sup>4</sup>; amisulpride significantly increased each of these parameters from baseline to day 28 (all  $p < 0.05$ ).<sup>53</sup> However, no significant change was found in any of these side effects in the CBD group, and the between-treatment difference was significant (all  $p < 0.01$ ), with CBD demonstrating a markedly superior side-effect profile.<sup>53</sup> The finding of greater tolerability, against a backdrop of similar efficacy, is particularly promising because compliance and adherence to current antipsychotic treatments are hindered by their often severe side-effect profiles.<sup>4</sup> Nonadherence, in turn, is associated with poorer prognosis (such as a more severe

relapsing-remitting course) and worse functional outcomes.<sup>58</sup> A novel antipsychotic without such side-effects could therefore lead to improved adherence and better outcomes. Finally, with a view to understanding the mechanisms by which CBD may have its antipsychotic effects, serum anandamide concentrations were measured before and after treatment in both groups.<sup>53</sup> As predicted by the authors, anandamide levels were significantly higher in the CBD-treated group relative to the amisulpride group, but perhaps more interesting was the finding of a significant association between the increase in anandamide and reduction in psychotic symptoms in the CBD group ( $p = 0.0012$ ).<sup>53</sup> These findings support the idea that the antipsychotic effects of CBD may be related to its inhibition of anandamide degradation.<sup>53</sup> This concurs with previous work showing that anandamide levels are increased in psychotic disorders (as reviewed by Minichino and colleagues)<sup>8</sup> with higher levels associated with less severe symptomatology.<sup>59–62</sup>

*CBD as adjunctive treatment.* More recently, in a 6-week multicentre, randomised, double-blind, parallel-group trial, CBD (1000 mg/day;  $n = 43$ ) was compared with placebo ( $n = 45$ ) as an add-on treatment to existing antipsychotic regimens in patients with schizophrenia.<sup>55</sup> There was a significant reduction in PANSS positive symptoms from baseline to 6-week study endpoint in the CBD compared with the placebo group (PANSS treatment difference =  $-1.4$ , 95% CI =  $-2.5$  to  $-0.2$ ;  $p = 0.019$ ). CBD-treated patients were also more likely to have been rated as improved (Clinical Global Impression Scale; CGI-I treatment difference =  $-0.5$ , 95% CI =  $-0.8$  to  $-0.1$ ;  $p = 0.018$ ) and as not severely unwell ( $-0.3$ , 95% CI =  $-0.5$  to  $0.0$ ;  $p = 0.044$ ) by the treating clinician.<sup>55</sup> Although the magnitude of these effects appears modest, it is common for treatments to fail in add-on trial designs because the tested treatment needs to show an effect over and above that of the existing treatment (here, antipsychotics, which have relatively large effect sizes).<sup>4,63,64</sup> The fact that CBD produced such an additional effect over that of concomitant antipsychotic treatment is therefore promising. There were also numerical (but non-significant) increases in the level of general functioning [Global Assessment of Functioning (GAF) scale treatment difference =  $3.0$ , 95% CI =  $-0.4$  to  $6.4$ ;  $p = 0.08$ ] and cognitive performance in the CBD treatment arm compared with the placebo arm, but no significant differences emerged in a number of other outcomes, including on negative,



**Table 1.** Overview of studies investigating cannabidiol in patients with psychosis.

Study	Design	CBD regimen	Outcome assessment	Results
Zuardi <sup>48</sup>	One patient with schizophrenia; open label case-report	Up to 1500 mg/day for 4 weeks	BPRS	Significant reduction in positive symptoms
Zuardi <sup>49</sup>	3 treatment-resistant patients with schizophrenia; open-label monotherapy case series	Up to 1280 mg/day for 4 weeks	BPRS	Mild improvement in one patient, no response in two patients
Zuardi <sup>50</sup>	Six patients with Parkinson's disease with psychotic symptoms; open-label pilot study	Up to 600 mg/day for 4 weeks	BPRS, Parkinson Psychosis Questionnaire	Significant reduction in psychotic symptoms
Zuardi <sup>51</sup>	Two patients with bipolar I disorder experiencing a manic episode with psychotic features; rater-blinded case series	Up to 1200 mg/day for 24 days	Young Mania Rating Scale, BPRS	No symptomatic improvement after CBD monotherapy either alone ( $n=1$ ) or in addition to improvements following CBD plus olanzapine ( $n=1$ )
Hallak <sup>52</sup>	28 patients with schizophrenia; baseline performance compared with that after placebo ( $n=10$ ), 300 mg CBD ( $n=9$ ) or 600 mg CBD ( $n=9$ ) administration 1 month later	Single dose of 300 or 600 mg	Stroop Colour Word Test	Stroop test performance significantly improved in placebo and 300 mg CBD group; numerical (nonsignificant) improvement in 600 mg CBD group
Leweke <sup>53</sup>	39 patients with schizophrenia; randomised, double-blind, monotherapy trial of CBD ( $n=19$ ) compared with the antipsychotic amisulpride ( $n=20$ )	Up to 800 mg/day for 4 weeks	BPRS, PANSS	Significant reduction in positive, negative, total and general symptoms in both groups. Significantly fewer side-effects in CBD group
Leweke <sup>54</sup>	29 patients with schizophrenia; randomised, double-blind, placebo-controlled crossover study	600 mg/day for 2 weeks	PANSS	Numerical but nonsignificant improvement in psychotic symptoms associated with CBD treatment
McGuire <sup>55</sup>	88 patients with schizophrenia; randomised, double-blind trial of add-on CBD ( $n=43$ ) versus placebo ( $n=45$ )	1000 mg/day for 6 weeks	PANSS, CGI, GAF, Cognition	Significant reduction in positive symptoms and CBD-treated patients more likely rated as improved/not as severely unwell by treating clinicians (CGI)
Boggs <sup>56</sup>	36 patients with schizophrenia; randomised, double-blind trial of add-on CBD ( $n=18$ ) versus placebo ( $n=18$ )	600 mg/day for 6 weeks	PANSS, MATRICS	No effects of CBD on cognition or positive, negative or total symptoms
Bhattacharyya <sup>57</sup>	33 patients at CHR for psychosis; randomised, double-blind design; 16 CHR subjects assigned to CBD and 17 to placebo; 19 controls	Single dose of 600 mg	fMRI (brain activation during verbal learning task)	CBD normalised brain function in CHR individuals in regions where CHR individuals showed abnormal activation under placebo

BPRS, Brief Psychiatric Rating Scale; CBD, cannabidiol; CGI, Clinical Global Impression Scale; CHR, clinical high risk; fMRI, functional Magnetic Resonance Imaging; GAF, Global Assessment of Functioning Scale; MATRICS, MATRICS Consensus Cognitive Battery (MCCB); PANSS, Positive and Negative Syndrome Scale.

total and general PANSS scores.<sup>55</sup> The number of adverse events was similar between the CBD (30 adverse events in 15 patients) and the placebo (35 adverse events in 16 patients) treatment arms, with the most common side effects including diarrhoea, nausea and headache. Most side effects were mild and did not require intervention.

Using similar methodology in a 6-week, randomised, parallel-group trial, Boggs and colleagues compared 600 mg/day adjunctive CBD *versus* placebo in 36 stable, antipsychotic-treated patients with chronic schizophrenia.<sup>56</sup> In this latter study, there were no effects of adjunctive CBD relative to placebo on positive, negative or total PANSS symptoms, nor were there any effects on cognitive performance (the primary outcome of the trial, measured using the MATRICS consensus battery; MCCB). In fact, only the placebo group were found to have improved MCCB composite scores over time, which the authors suggest may be due to regression to the mean or practice effects, with this pattern not seen in the CBD group, perhaps due to increased sedation or inhibited learning effects.<sup>56</sup> Overall, CBD was well tolerated, with no worsening of psychosis, mood, suicidality or movement side effects.

The reasons for the contrasting results with the two larger clinical trials remain unclear and warrant consideration.<sup>53,55</sup> One factor could be the lower CBD dose (600 mg/day) used by Boggs and colleagues,<sup>56</sup> compared with the higher doses of 800 and 1000 mg/day in the earlier trials.<sup>53,55</sup> While 600 mg (even as a single acute dose) has been shown to modulate brain function across a variety of tasks in healthy individuals, and can prevent the acute induction of psychotic symptoms following THC,<sup>24</sup> it is possible that a higher therapeutic dose is needed in the context of patients with psychosis.<sup>56</sup> This is consistent with the results from a further earlier study, which also used 600 mg/day in patients with schizophrenia, and which showed nonsignificant results for total PANSS symptom reduction,<sup>54</sup> although there were also a number of design issues associated with this study. Research conducted outside of the psychosis literature suggests that specific effects of CBD follow an inverted-U dose-response curve. This could have pragmatic implications for CBD as a novel pharmacotherapy because individual-patient dose titration would introduce practical challenges in the clinic. In two studies testing multiple doses of acute CBD against anxiety induced by public speaking, only

the intermediate doses of CBD (300 mg) significantly reduced anxiety while lower and higher doses did not.<sup>65,66</sup> Animal models of anxiety confirm this dose-response effect, with anxiolytic effects observed at lower doses which disappear at higher doses.<sup>12,67</sup> However, the dose-response range is thought to be narrower for the anxiolytic compared with the antipsychotic effects of CBD,<sup>67,68</sup> at least in preclinical studies.<sup>28</sup> Higher doses are also likely required for antipsychotic *versus* anxiolytic effects (for review see Crippa and colleagues).<sup>12</sup> Future research is required to determine the precise dose-response ranges for specific therapeutic (i.e. antipsychotic and anxiolytic) effects for specific psychotic disorders and other clinical populations.<sup>12</sup>

Other possible factors that may explain lack of beneficial effect of CBD treatment in the study by Boggs and colleagues may relate to illness stage and symptom severity of the respective samples.<sup>56</sup> The participants in the negative Boggs and colleagues study were older (mean age = 47) and had chronic schizophrenia with stable symptoms, whereas those in the study of Leweke and colleagues were younger (mean age = 30) and were included only if they specifically had an acute exacerbation of psychotic symptoms.<sup>53</sup> This is reflected in the higher mean baseline symptom scores in the Leweke study (PANSS total = 93; positive = 24) compared with the Boggs and colleagues study (total = 80; positive = 20).<sup>53,56</sup> However, the negative findings are harder to reconcile with the positive findings of McGuire and colleagues,<sup>55</sup> where the levels of symptoms were comparable (PANSS total = 80; positive = 18) and the mean age was 41 years. The Boggs and colleagues and McGuire and colleagues studies also took a similar methodological approach (add-on design),<sup>55,56</sup> although the McGuire study had much higher statistical power ( $n = 88$  *versus*  $n = 36$ ). Together, these findings may suggest that younger patients in an earlier stage of illness may benefit more from CBD treatment, potentially because intervening early arrests pathophysiological processes before more severe or enduring neural changes (that may be less amenable to later intervention) take place.<sup>5</sup> A further potential difference between the studies relates to the existing antipsychotic treatment regimens within the add-on design. While McGuire and colleagues provide specific data on the exact antipsychotic medications used by their sample, only summary classification data are provided by Boggs and colleagues.<sup>55,56</sup> Nevertheless, in comparison, over 90% of the antipsychotics used in both the

CBD and placebo groups from the McGuire study were second-generation, and only ~8% were first-generation. However, in the Boggs study, 55% of the CBD group and 72% of the placebo group were taking second-generation antipsychotics, while 50% of the CBD group and 28% of the placebo group were taking first-generation. Current evidence suggests there are small but significant differences in efficacy between different individual antipsychotics within both first and second-generation classifications.<sup>4</sup> It is therefore possible that the different baseline mix of concurrent antipsychotics could be a contributing factor to the disparity in results.

#### *Potential effects of CBD on cognition*

The psychopathology associated with psychotic disorders is often thought of in terms of positive and negative symptoms. However, cognitive dysfunction is a prominent feature that is strongly associated with loss of social/occupational function and disability.<sup>69,70</sup> Cognitive symptoms are also refractory to any type of current treatment.<sup>2</sup> A number of initial studies have examined whether CBD may improve aspects of cognition in patients with psychosis.

As outlined above, the clinical trial by Boggs and colleagues observed no significant effects of CBD on cognition, which was the study's primary outcome.<sup>56</sup> The largest clinical trial of CBD in patients with psychosis also assessed cognition, using the Brief Assessment of Cognition in Schizophrenia (BACS).<sup>55</sup> While there were no statistically significant effects of CBD on cognition overall, there were numerical increases in BACS composite score, motor speed performance and executive functioning in the CBD relative to the placebo group.<sup>55</sup> Studies of CBD administration in healthy people also show that CBD can attenuate the acute amnesic effects of THC administration,<sup>23</sup> while it does not appear to affect learning and memory in the absence of existing impairments.<sup>71</sup>

A separate study examined the acute effects of a single dose of CBD on cognitive function in 28 patients with schizophrenia.<sup>52</sup> Performance on the Stroop Colour Word Test, which indexes selective attention, was compared at baseline (no drug) to one of three parallel-arm conditions 1 month later: placebo ( $n=10$ ), 300 mg CBD ( $n=9$ ) and 600 mg CBD ( $n=9$ ). While performance improved (numerically) in all three arms

from baseline to the second session, indicating a learning effect, only those receiving placebo and the lower CBD dose (300 mg) showed a statistically significant improvement.<sup>52</sup> The authors suggest that sedative effects of CBD may underlie the lack of improvement (related to learning/practice effects) in the higher-dose CBD group. Overall, whether CBD has beneficial effects on cognition in patients with psychosis is currently unclear and remains an important avenue for future research.

#### *Early intervention: prior to psychosis onset*

CBD has also been indicated for use prior to the onset of psychosis in patients at clinical high risk for the disorder. These individuals present with clinically significant attenuated psychotic symptoms and have 20–30% risk of developing psychosis within 2 years.<sup>72</sup> Accumulating evidence suggests that the pathophysiological processes driving psychosis evolve over the course of the disorder, with the clinical high-risk state offering a unique opportunity for preventative intervention.<sup>5</sup> However, recent meta-analyses have concluded that existing treatments are not effective for preventing transition to psychosis nor for reducing symptoms,<sup>73,74</sup> representing a significant unmet clinical need. Furthermore, because many of these individuals will not transition to psychosis, pharmacotherapies also need to be safe and well tolerated.

Using a randomised, double-blind, placebo-controlled, parallel-arm design, 33 antipsychotic-naïve individuals at clinical high risk for psychosis and 19 healthy controls were studied using a verbal learning fMRI task.<sup>57</sup> A total of 16 high-risk subjects received a single oral dose of CBD (600 mg) and 17 received placebo. Control participants were not given any drug. The results showed that a single dose of CBD normalised brain function in clinical high-risk individuals in regions where high-risk individuals showed abnormal activation under placebo conditions. These specific regions, including the hippocampus, midbrain and striatum, are also strongly implicated in the pathophysiology of psychosis onset.<sup>75,76</sup> The normalisation of aberrant brain function in these regions by CBD could underlie the therapeutic effects observed in previous studies in patients with established psychosis and anxiety disorders.<sup>53,55,77</sup>

In terms of effects following continued treatment, results from the same study investigating the effect of 3-week treatment with CBD (600 mg/day) on symptoms and functional brain activation are



awaited.<sup>78</sup> In summary, initial evidence supports CBD as a potential novel treatment for people at clinical high risk for psychosis, and its benign side-effect profile as evident from other data (see below) makes it a particularly suitable candidate treatment for this patient group. Whether CBD can actually alter the course of the disorder and prevent the onset of psychosis will require larger-scale clinical trials over longer durations. Such studies have recently been initiated and the results are anticipated to make a significant contribution to the evidence base.

### *Psychosis in nonschizophrenia spectrum disorders*

Additional complementary evidence for the use of CBD in psychosis comes from a study of Parkinson's disease psychosis. In a small, open-label pilot study, six patients with Parkinson's disease psychosis received oral CBD for 4 weeks, titrated from a mean dose of 150–400 mg/day in addition to their current treatment regimens.<sup>50</sup> CBD was associated with a significant decrease in psychotic symptoms and was well tolerated, with no side effects clinically observed. CBD also improved total scores on the Unified Parkinson's Disease Rating Scale and did not worsen cognition or motor function. While caution is warranted due to the small sample size and lack of placebo control, these results support the view that CBD is safe, well-tolerated and may have efficacy for the treatment of psychosis in nonschizophrenia spectrum disorders. Phase II clinical trials of CBD for Parkinson's disease psychosis and behavioural symptoms (including psychotic symptoms) in Alzheimer's disease are now being planned.

In addition to its antipsychotic properties, the wider pharmacological profile of CBD, which includes anxiolytic, sedative, anticonvulsant and thus potential mood-stabilising effects, raises the possibility of therapeutic potential for bipolar disorder (with or without psychosis) as well as unipolar mood disorders.<sup>12,79</sup> Aside from anecdotal reports,<sup>79</sup> CBD has so far been tested in two patients with bipolar I disorder experiencing a manic episode with psychotic features.<sup>51</sup> Two female inpatients received placebo for 5 days, followed by oral CBD titrated from 600 to 1200 mg/day for 24 days. One patient received concomitant olanzapine between day 6 and 20, while the other patient did not. Symptoms were assessed using the BPRS and Young Mania

Rating Scale. CBD provided no additional benefit over that seen after combined CBD and olanzapine treatment in the first patient, and there was no benefit of CBD monotherapy in the second patient.<sup>51</sup> These negative findings concur with the lack of CBD effects seen in an animal (hyperlocomotion) model of mania.<sup>80</sup> Nevertheless, whether CBD is effective for other specific symptoms in bipolar disorder (such as bipolar depression and anxiety) is currently unknown but clinical trials are now underway.<sup>12</sup> While outside the remit of this review, it is also worth noting that CBD has purported antidepressant-like effects (albeit so far in preclinical studies), thought to be mediated by serotonin 5-HT<sub>1A</sub> receptors,<sup>81</sup> which could suggest therapeutic potential for mood disorders such as depression.<sup>12,28</sup>

### *Safety and side effects*

While CBD has been found to be safe and well tolerated in the three (relatively short-term) clinical trials in psychosis to date,<sup>53,55,56</sup> the total volume of data is still small and thus insufficient adverse events may yet have accumulated. When measured in terms of 'patient-years' (i.e. the number of patients treated with a new drug multiplied by the duration of treatment), data from at least 1000 patient-years or more are recommended for robust estimates of safety and tolerability.<sup>82</sup> This follows the notion that the greater the clinical use and experience of prescribing drugs in different clinical scenarios, the better (and more nuanced) our knowledge of its true risk-benefit profile. However, 1000 patient-years equates to, for example, 1000 patients taking CBD for 1 year or 500 patients for 2 years. The largest RCT of CBD in psychosis to date randomised 43 patients to receive CBD for 6 weeks.<sup>55</sup> This highlights the significant gap between the current state of knowledge and the benchmark for sufficient risk-benefit evidence. Larger randomised controlled trials with longer durations of treatment are therefore needed.

Considering the wider literature (not restricted to studies in psychosis), doses of up to 1500 mg/day have been well tolerated in humans with few or no side effects, although such doses have mainly been administered to very few patients in case series reports.<sup>28,48,49</sup> The first comprehensive review of CBD-related (*in vivo* and *in vitro*) side effects suggested that CBD is nontoxic in cell lines and has no adverse effects on physiological parameters such as heart rate, blood pressure and

body temperature, gastrointestinal transit, and psychomotor or psychological function.<sup>83</sup> A second review extended these findings and confirmed that overall, CBD has a favourable safety profile.<sup>84</sup> However, CBD is not entirely side-effect free; *in vitro* work suggests that CBD may affect cell viability, fertilisation potential and drug transporter/P-glycoprotein function,<sup>83,84</sup> and reports of (mostly mild) clinical adverse effects are starting to accumulate as the body of available literature becomes substantiated. The most common adverse effects in clinical studies include diarrhoea, tiredness or sedation, and changes in appetite and weight.<sup>83</sup>

**Sedation.** The idea that CBD may induce sedation is a recurring theme,<sup>52,56</sup> and there are numerous purported links between the endocannabinoid system and the sleep–wake cycle. One of the earliest studies showed that 600 mg of CBD induced sedation in a small sample of healthy people.<sup>85</sup> In people with insomnia, a therapeutic effect suggestive of sedation (increased sleep time, less frequent awakenings) was noted after 160 mg/day CBD.<sup>86</sup> However, other studies have shown that CBD counteracts the sedative effects of THC,<sup>87</sup> and a recent study investigating the effects of 300 mg CBD (*versus* placebo) on the sleep–wake cycle reported no effects on sedation, albeit this was in healthy individuals.<sup>88</sup> A review concluded that this effect is dose-based, with lower doses having a stimulating effect on the sleep–wake cycle, but higher doses having a sedative effect.<sup>89</sup> Given the aforementioned evidence that higher doses of CBD are likely needed to produce antipsychotic effects, particularly in patients with psychotic disorders (e.g. 800 mg/day or more), sedative side effects may be particularly prevalent when used for this indication and warrant further investigation.

**Gastrointestinal.** Studies in epilepsy report diarrhoea in approximately 15–20% of CBD-treated individuals.<sup>90</sup> In the largest study in patients with psychosis, 9% of those receiving CBD *versus* 4% receiving placebo reported this side effect.<sup>55</sup> While the severity was often mild and resolved without treatment, the one withdrawal (out of  $n = 43$ ) in the CBD group was due to nausea, diarrhoea, abdominal pain and vomiting.<sup>55</sup> Despite the initial review by Bergamaschi and colleagues suggesting no effects on gastric motility,<sup>83</sup> the emerging pattern of findings is that diarrhoea is one of the most common side effects of CBD. This suggests that it does, in fact, increase gastrointestinal transit in humans which could affect its ultimate acceptability.<sup>84</sup>

**Hepatic drug metabolism.** CBD is a potent inhibitor of CYP3A4 and CYP2D6, which belong to the cytochrome P450 family of enzymes that together metabolise more than 60% of prescribed drugs, including many antidepressants, antipsychotics and benzodiazepines.<sup>91–94</sup> CBD could, therefore, have effects on the circulating concentrations of other medications.<sup>83</sup> In the context of psychosis, where concomitant antipsychotic treatment is likely, such effects could require careful monitoring and dose adjustment.

**Liver enzymes.** A meta-analysis of studies conducted in epilepsy found that CBD was associated with significantly increased serum aminotransferases, with a risk ratio of 14.14 (95% CI = 4.48–44.60) in studies using 20 mg/kg CBD.<sup>91</sup> While the potential for hepatic toxicity was identified in this meta-analysis, no events within the individual studies met criteria for lasting liver injury (i.e. based on bilirubin).<sup>91</sup> Monitoring of hepatic function, particularly during the first 30 days of treatment, is therefore recommended.<sup>91,95</sup> Given the potentially serious nature and consequences of this potential side effect, future research should attempt to evaluate such effects (and in additional patient populations).

**Unregulated over-the-counter CBD products.** One consequence of the explosion of public interest in CBD is that a vast array of unregulated products, purporting to contain CBD, are now widely available from online and high-street stores.<sup>96</sup> These products should explicitly not be used for medicinal purposes (for review see Freeman and colleagues)<sup>96</sup> because they are unregulated, not pharmaceutical grade nor produced under good manufacturing practice conditions;<sup>96</sup> their ingredients and dose are uncontrolled, with existing evidence showing that dosage is highly variable and contrary to labelling<sup>97</sup>; and there is the potential for such products to be contaminated with high levels of other cannabinoids (such as THC),<sup>96–98</sup> which could be detrimental to mental health and especially harmful to those with psychotic disorders. At best, such products represent an expensive placebo due to the typically low doses of CBD per administration (e.g. 25 mg/dose compared with 600–1000 mg/day in clinical studies),<sup>48,55,96</sup> but at worst, these products could be actively harmful due to the high risk of contamination with other cannabinoids. This is particularly the case for individuals with psychotic disorders, but also for children, young adults and adolescents, where cannabinoid exposure during

these critical periods of brain development and maturation could have particularly severe and enduring pervasive effects.<sup>99</sup>

In summary, CBD appears to show a favourable safety and tolerability profile but there remains a paucity of data, particularly in terms of chronic exposure in humans. Whether CBD has adverse effects on liver enzymes and hepatic metabolism, and thus potential interactions with other drugs, remains an important avenue for future research. Going forward, future clinical trials should aim to collect explicit information regarding side effects. While these future studies may indeed show that CBD is associated with common gastrointestinal and possibly sedative side effects, the risk–benefit ratio may still be favourable, especially when compared with the current status quo of treatments for psychosis: antipsychotics.

#### Potential mechanisms underlying the antipsychotic effects of cannabidiol

The idea that CBD may have therapeutic potential emerged from observations that it has opposite effects to THC at the pharmacological/molecular, neural (systems) and behavioural level.<sup>24,28,42</sup> The main molecular target for THC is the CB1 receptor, where it has partial agonist effects.<sup>25</sup> The molecular mechanisms of CBD are less clear, but its demonstrable ability to attenuate the effects of THC led to the notion that it may be an inverse agonist/antagonist at CB1 receptors. Although, in contrast to THC, CBD has low affinity for CB1,<sup>25</sup> it does appear to ‘antagonise the agonists’ of this receptor even at relatively low concentrations,<sup>100</sup> potentially *via* negative allosteric modulation.<sup>101</sup>

Another mechanism by which CBD may have antipsychotic effects is *via* upregulation of the endocannabinoid anandamide, likely by inhibiting its degrading enzyme, fatty acid amide hydrolase.<sup>53,102</sup> This is consistent with the aforementioned findings of Lewke and colleagues,<sup>53</sup> where CBD increased serum anandamide levels in patients with psychosis, with this increase significantly associated with the concomitant reduction in psychotic symptoms. Additional pharmacological effects of CBD that have been described include activation of 5-HT1A receptors,<sup>103</sup> transient receptor potential vanilloid type 1,<sup>102</sup> GPR55 receptors and potentially various other mechanisms.<sup>25,104,105,106</sup>

CB1 receptors are widely expressed in brain with the highest concentrations in mesocorticolimbic regions.<sup>107–110</sup> Consistent with this distribution, based on human experimental studies involving cannabinoid administration, CB1 receptors appear to be involved in numerous cognitive processes subserved by corticolimbic circuitry,<sup>44,111</sup> such as learning and memory,<sup>24,47</sup> salience processing,<sup>39,40</sup> and response inhibition,<sup>24</sup> which are also known to be impaired in patients with psychosis.<sup>111</sup> Abundant evidence from experimental studies of healthy volunteers shows that CBD modulates brain function (in the opposite direction to THC) during each of these cognitive processes in their respective neural substrates.<sup>24,39,40,47</sup> This suggests that, at the brain systems level, the mechanism of the antipsychotic effects of CBD may be mediated through modulation of function of these neural substrates. Consistent with this, in patients at clinical high risk for psychosis, CBD was also found to normalise activation in key brain regions strongly implicated in psychosis onset and psychotic symptoms (such as the hippocampus, midbrain and striatum).<sup>57,75,76</sup>

#### Conclusion

Initial clinical trials suggest that CBD is safe, well-tolerated and may have antipsychotic effects in patients with psychosis. There is some indication that CBD may be particularly effective in the early stages of the disorder, such as in patients at clinical high risk and those with first episode psychosis. Neuroimaging research suggests that CBD may exert its therapeutic effects *via* modulation of brain function in regions known to be altered in patients with psychosis across a variety of cognitive paradigms. Questions remain regarding the full side-effect profile of CBD, with reports of increased liver enzymes and potential for hepatic toxicity, but the most commonly reported side effects (such as diarrhoea and sedation) are likely to be both mild and benign. A more substantial body of evidence, including larger studies with longer-term CBD administration (e.g. up to 2 years), is required to accurately estimate the risk–benefit profile of CBD. Pending such evidence, if CBD treatment were ultimately associated mainly with common sedative and gastrointestinal side effects, these would likely still indicate a favourable tolerability profile compared with the side-effect profiles of currently licensed antipsychotic treatments. Given that CBD has antipsychotic effects without directly acting on dopamine receptors, it could represent

a completely novel class of treatment for psychosis. CBD may also have therapeutic value prior to the onset of frank psychosis in patients at clinical high risk for the disorder, and in patients with nonschizophrenia spectrum disorder psychosis, such as Parkinson's disease. Unregulated over-the-counter products containing CBD should explicitly not be used for medicinal purposes. In sum, CBD currently represents a promising potential novel treatment for patients with psychosis. If the success observed in initial clinical studies are replicated in large-scale trials with chronic administration, CBD has the potential to become the first licensed nondopaminergic treatment for psychosis.

### Funding

The authors disclosed receipt of the following financial support for the research, authorship, and publication of this article: SB has been supported by grants from the UK Medical Research Council (MRC) (MR/J012149/1) and the National Institute for Health Research (NIHR Clinician Scientist Award; NIHR CS-11-001). SB has also been supported by the NIHR Mental Health Biomedical Research Centre (BRC) at South London and Maudsley National Health Service (NHS) Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the MRC or the Department of Health and Social Care. The funders had no role in the preparation, review, or approval of the manuscript and decision to submit the manuscript for publication.

### Conflict of interest statement

The authors declare that there is no conflict of interest.

### Ethical Statement

Ethical approval was not required because this is a review.

### ORCID iD

Cathy Davies  <https://orcid.org/0000-0003-3011-8643>

### References

1. Charlson FJ, Ferrari AJ, Santomauro DF, *et al.* Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. *Schizophr Bull* 2018; 44: 1195–1203.
2. Insel TR. Rethinking schizophrenia. *Nature* 2010; 468: 187–193.
3. Samara MT, Nikolakopoulou A, Salanti G, *et al.* How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? An analysis based on individual patient data from randomized controlled trials. *Schizophr Bull* 2019; 45: 639–646.
4. Leucht S, Cipriani A, Spineli L, *et al.* Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet* 2013; 382: 951–962.
5. Millan MJ, Andrieux A, Bartzokis G, *et al.* Altering the course of schizophrenia: progress and perspectives. *Nat Rev Drug Discov* 2016; 15: 485–515.
6. Fernandez-Espejo E, Viveros MP, Núñez L, *et al.* Role of cannabis and endocannabinoids in the genesis of schizophrenia. *Psychopharmacology (Berl)* 2009; 206: 531–549.
7. Leweke FM, Mueller JK, Lange B, *et al.* Role of the endocannabinoid system in the pathophysiology of schizophrenia: implications for pharmacological intervention. *CNS Drugs* 2018; 32: 605–619.
8. Minichino A, Senior M, Brondino N, *et al.* Measuring disturbance of the endocannabinoid system in psychosis. *JAMA Psychiatry*. Epub ahead of print 5 June 2019. DOI: 10.1001/jamapsychiatry.2019.0970.
9. Volk DW and Lewis DA. The role of endocannabinoid signaling in cortical inhibitory neuron dysfunction in schizophrenia. *Biol Psychiatry* 2016; 79: 595–603.
10. Ceccarini J, De Hert M, Van Winkel R, *et al.* Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. *Neuroimage* 2013; 79: 304–312.
11. Borgan F, Laurikainen H, Veronese M, *et al.* In vivo availability of cannabinoid 1 receptor levels in patients with first-episode psychosis. *JAMA Psychiatry*. Epub ahead of print 3 July 2019. DOI: 10.1001/jamapsychiatry.2019.1427.
12. Crippa JA, Guimarães FS, Campos AC, *et al.* Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age. *Front Immunol* 2018; 9: 1–16.
13. Marconi A, Di Forti M, Lewis CM, *et al.* Meta-analysis of the association between the level of cannabis use and risk of psychosis. *Schizophr Bull* 2016; 42: 1262–1269.



14. Schoeler T, Monk A, Sami MB, *et al.* Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. *Lancet Psychiatry* 2016; 3: 215–225.
15. Schoeler T, Petros N, Di Forti M, *et al.* Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. *Lancet Psychiatry* 2016; 3: 947–953.
16. Large M, Sharma S, Compton MT, *et al.* Cannabis use and earlier onset of psychosis: a systematic meta-analysis. *Arch Gen Psychiatry* 2011; 68: 555–561.
17. Schoeler T, Petros N, Forti M Di, *et al.* Association between continued cannabis use and risk of relapse in first-episode psychosis a quasi-experimental investigation within an observational study. *JAMA Psychiatry* 2016; 73: 1173–1179.
18. Patel R, Wilson R, Jackson R, *et al.* Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study. *BMJ Open* 2016; 6: 1–9.
19. Schoeler T, Petros N, Di Forti M, *et al.* Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis. *Lancet Psychiatry* 2017; 4: 627–633.
20. Di Forti M, Marconi A, Carra E, *et al.* Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. *Lancet Psychiatry* 2015; 2: 233–238.
21. Di Forti M, Sallis H, Allegri F, *et al.* Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. *Schizophr Bull* 2014; 40: 1509–1517.
22. Schoeler T, Petros N, Di Forti M, *et al.* Effect of continued cannabis use on medication adherence in the first two years following onset of psychosis. *Psychiatry Res* 2017; 255: 36–41.
23. Englund A, Morrison PD, Nottage J, *et al.* Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. *J Psychopharmacol* 2013; 27: 19–27.
24. Bhattacharyya S, Morrison PD, Fusar-Poli P, *et al.* Opposite effects of  $\Delta^9$ -tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. *Neuropsychopharmacology* 2010; 35: 764–774.
25. Pertwee RG. The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids:  $\Delta^9$ -tetrahydrocannabinol, cannabidiol and  $\Delta^9$ -tetrahydrocannabivarin. *Br J Pharmacol* 2008; 153: 199–215.
26. Jones C, Watson D and Fone K. Animal models of schizophrenia. *Br J Pharmacol* 2011; 164: 1162–1194.
27. Moreira FA and Guimarães FS. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. *Eur J Pharmacol* 2005; 512: 199–205.
28. Zuardi A, Crippa J, Hallak J, *et al.* A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. *Curr Pharm Des* 2012; 18: 5131–5140.
29. Mena A, Ruiz-Salas JC, Puentes A, *et al.* Reduced prepulse inhibition as a biomarker of schizophrenia. *Front Behav Neurosci* 2016; 10: 1–9.
30. Peres FF, Diana MC, Levin R, *et al.* Cannabidiol administered during peri-adolescence prevents behavioral abnormalities in an animal model of schizophrenia. *Front Pharmacol* 2018; 9: 1–15.
31. Modinos G, Allen P, Grace AA, *et al.* Translating the MAM model of psychosis to humans. *Trends Neurosci* 2015; 38: 129–138.
32. Stark T, Ruda-Kucerova J, Iannotti FA, *et al.* Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. *Neuropharmacology* 2019; 146: 212–221.
33. Malone DT, Jongejan D and Taylor DA. Cannabidiol reverses the reduction in social interaction produced by low dose  $\Delta^9$ -tetrahydrocannabinol in rats. *Pharmacol Biochem Behav* 2009; 93: 91–96.
34. Peres FF, Diana MC, Suiama MA, *et al.* Peripubertal treatment with cannabidiol prevents the emergence of psychosis in an animal model of schizophrenia. *Schizophr Res* 2016; 172: 220–221.
35. Gomes FV, Llorente R, Del Bel EA, *et al.* Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol. *Schizophr Res* 2015; 164: 155–163.
36. Esposito G, Scuderi C, Valenza M, *et al.* Cannabidiol reduces A $\beta$ -induced neuroinflammation and promotes hippocampal neurogenesis through PPAR $\gamma$  involvement. *PLoS One* 2011; 6: e28668.
37. Fagherazzi EV, Garcia VA, Maurmann N, *et al.* Memory-rescuing effects of cannabidiol in an



- animal model of cognitive impairment relevant to neurodegenerative disorders. *Psychopharmacology (Berl)* 2012; 219: 1133–1140.
38. Morgan CJA, Schafer G, Freeman TP, *et al.* Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. *Br J Psychiatry* 2010; 197: 285–290.
  39. Bhattacharyya S, Crippa JA, Allen P, *et al.* Induction of psychosis by  $\Delta^9$ -tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. *Arch Gen Psychiatry* 2012; 69: 27–36.
  40. Bhattacharyya S, Falkenberg I, Martin-Santos R, *et al.* Cannabinoid modulation of functional connectivity within regions processing attentional salience. *Neuropsychopharmacology* 2015; 40: 1343–1352.
  41. Steeds H, Carhart-Harris RL and Stone JM. Drug models of schizophrenia. *Ther Adv Psychopharmacol* 2015; 5: 43–58.
  42. Bhattacharyya S, Crippa J, Martin-Santos R, *et al.* Imaging the neural effects of cannabinoids: current status and future opportunities for psychopharmacology. *Curr Pharm Des* 2009; 15: 2603–2614.
  43. D'Souza DC, Perry E, MacDougall L, *et al.* The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. *Neuropsychopharmacology* 2004; 29: 1558–1572.
  44. Colizzi M and Bhattacharyya S. Neurocognitive effects of cannabis: lessons learned from human experimental studies. *Prog Brain Res* 2018; 242: 179–216.
  45. Colizzi M, Weltons N, McGuire P, *et al.* Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis. *Mol Psychiatry*. Epub ahead of print 15 February 2019. DOI: 10.1038/s41380-019-0374-8.
  46. Bhattacharyya S, Atakan Z, Martin-Santos R, *et al.* Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of  $\Delta^9$ -tetrahydrocannabinol on midbrain and striatal function. *Mol Psychiatry* 2012; 17: 1152–1155.
  47. Bhattacharyya S, Fusar-Poli P, Borgwardt S, *et al.* Modulation of mediotemporal and ventrostriatal function in humans by  $\Delta^9$ -tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. *Arch Gen Psychiatry* 2009; 66: 442–451.
  48. Zuardi AW, Morais SL, Guimarães FS, *et al.* Antipsychotic effect of cannabidiol. *J Clin Psychiatry* 1995; 56: 485–486.
  49. Zuardi AW, Hallak JEC, Dursun SM, *et al.* Cannabidiol monotherapy for treatment-resistant schizophrenia. *J Psychopharmacol* 2006; 20: 683–686.
  50. Zuardi AW, Crippa JA, Hallak JE, *et al.* Cannabidiol for the treatment of psychosis in Parkinsons disease. *J Psychopharmacol* 2009; 23: 979–983.
  51. Zuardi AW, Crippa JAS, Dursun SM, *et al.* Cannabidiol was ineffective for manic episode of bipolar affective disorder. *J Psychopharmacol* 2010; 24: 135–137.
  52. Hallak JEC, Machado-de-Sousa JP, Crippa JAS, *et al.* Performance of schizophrenic patients in the stroop color word test and electrodermal responsiveness after acute administration of cannabidiol (CBD). *Rev Bras Psiquiatr* 2010; 32: 56–61.
  53. Leweke FM, Piomelli D, Pahlisch F, *et al.* Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. *Transl Psychiatry* 2012; 2: e94.
  54. Leweke FM, Hellmich M, Pahlisch F, *et al.* Modulation of the endocannabinoid system as a potential new target in the treatment of schizophrenia. *Schizophr Res* 2014; 153: S47.
  55. McGuire P, Robson P, Cubala WJ, *et al.* Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. *Am J Psychiatry* 2018; 175: 225–231.
  56. Boggs DL, Surti T, Gupta A, *et al.* The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. *Psychopharmacology (Berl)* 2018; 235: 1923–1932.
  57. Bhattacharyya S, Wilson R, Appiah-Kusi E, *et al.* Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial. *JAMA Psychiatry* 2018; 75: 1107–1117.
  58. Novick D, Haro JM, Suarez D, *et al.* Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. *Psychiatry Res* 2010; 176: 109–113.

59. Giuffrida A, Leweke FM, Gerth CW, *et al.* Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. *Neuropsychopharmacology* 2004; 29: 2108–2114.
60. Reuter AR, Bumb JM, Mueller JK, *et al.* Association of anandamide with altered binocular depth inversion illusion in schizophrenia. *World J Biol Psychiatry* 2017; 18: 483–488.
61. Leweke FM, Giuffrida A, Wurster U, *et al.* Elevated endogenous cannabinoids in schizophrenia. *Neuroreport* 1999; 10: 1665–1669.
62. Leweke FM, Giuffrida A, Koethe D, *et al.* Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. *Schizophr Res* 2007; 94: 29–36.
63. Shilling PD and Feifel D. Potential of oxytocin in the treatment of schizophrenia. *CNS Drugs* 2016; 30: 193–208.
64. Hirota T, Schwartz S and Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. *J Am Acad Child Adolesc Psychiatry* 2014; 53: 153–173.
65. Linares IM, Zuardi AW, Pereira LC, *et al.* Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. *Rev Bras Psiquiatr* 2019; 41: 9–14.
66. Zuardi AW, Rodrigues NP, Silva AL, *et al.* Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. *Front Pharmacol* 2017; 8: 1–9.
67. Guimarães FS, Chiaretti TM, Graeff FG, *et al.* Antianxiety effect of cannabidiol in the elevated plus-maze. *Psychopharmacology (Berl)* 1990; 100: 558–559.
68. Zuardi AW, Antunes Rodrigues J and Cunha JM. Effects of cannabidiol in animal models predictive of antipsychotic activity. *Psychopharmacology (Berl)* 1991; 104: 260–264.
69. Fatouros-Bergman H, Cervenka S, Flyckt L, *et al.* Meta-analysis of cognitive performance in drug-naïve patients with schizophrenia. *Schizophr Res* 2014; 158: 156–162.
70. Sheffield JM, Karcher NR and Barch DM. Cognitive deficits in psychotic disorders: a lifespan perspective. *Neuropsychol Rev* 2018; 28: 509–533.
71. Morgan CJA, Freeman TP, Hindocha C, *et al.* Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. *Transl Psychiatry* 2018; 8: 181.
72. Fusar-Poli P, Cappucciati M, Borgwardt S, *et al.* Heterogeneity of psychosis risk within individuals at clinical high risk. *JAMA Psychiatry* 2016; 73: 113–120.
73. Davies C, Cipriani A, Ioannidis JPA, *et al.* Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis. *World Psychiatry* 2018; 17: 196–209.
74. Davies C, Radua J, Cipriani A, *et al.* Efficacy and acceptability of interventions for attenuated positive psychotic symptoms in individuals at clinical high risk of psychosis: a network meta-analysis. *Front Psychiatry* 2018; 9: 1–17.
75. Allen P, Chaddock CA, Egerton A, *et al.* Resting hyperperfusion of the hippocampus, midbrain, and basal ganglia in people at high risk for psychosis. *Am J Psychiatry* 2016; 173: 392–399.
76. Lieberman JA, Girgis RR, Brucato G, *et al.* Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention. *Mol Psychiatry* 2018; 23: 1764–1772.
77. Crippa JAS, Derenusson GN, Ferrari TB, *et al.* Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. *J Psychopharmacol* 2011; 25: 121–130.
78. Bhattacharyya S, Wilson R, Allen P, *et al.* 17.3 effect of cannabidiol on symptoms, distress and neurophysiological abnormalities in clinical high-risk for psychosis patients: a placebo-controlled study. *Schizophr Bull* 2018; 44: S28.
79. Ashton CH, Moore PB, Gallagher P, *et al.* Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. *J Psychopharmacol* 2005; 19: 293–300.
80. Valvassori SS, Elias G, De Souza B, *et al.* Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania. *J Psychopharmacol* 2011; 25: 274–279.
81. Zanelati TV, Biojone C, Moreira FA, *et al.* Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT 1A receptors. *Br J Pharmacol* 2010; 159: 122–128.
82. Duijnhoven RG, Straus SMJM, Raine JM, *et al.* Number of patients studied prior to approval of new medicines: a database analysis. *PLoS Med* 2013; 10: 1–8.
83. Bergamaschi MM, Queiroz RHC, Zuardi AW, *et al.* Safety and side effects of cannabidiol, a

- cannabis sativa constituent. *Curr Drug Saf* 2011; 6: 237–249.
84. Iffland K and Grotenhermen F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. *Cannabis Cannabinoid Res* 2017; 2: 139–154.
  85. Zuardi AW, Guimarães FS and Moreira AC. Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. *Braz J Med Biol Res* 1993; 26: 213–217.
  86. Carlini EA and Cunha JM. Hypnotic and antiepileptic effects of cannabidiol. *J Clin Pharmacol* 1981; 21: 417S–427S.
  87. Nicholson AN, Turner C, Stone BM, *et al.* Effect of  $\Delta$ -9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. *J Clin Psychopharmacol* 2004; 24: 305–313.
  88. Linares IMP, Guimaraes FS, Eckeli A, *et al.* No acute effects of cannabidiol on the sleep-wake cycle of healthy subjects: a randomized, double-blind, placebo-controlled, crossover study. *Front Pharmacol* 2018; 9: 1–8.
  89. Babson KA, Sottile J and Morabito D. Cannabis, cannabinoids, and sleep: a review of the literature. *Curr Psychiatry Rep* 2017; 19: 23.
  90. Lattanzi S, Brigo F, Trinka E, *et al.* Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis. *Drugs* 2018; 78: 1791–1804.
  91. Yamaori S, Ebisawa J, Okushima Y, *et al.* Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. *Life Sci* 2011; 88: 730–736.
  92. Watanabe K, Yamaori S, Masuda K, *et al.* Cannabinoids as potent inhibitors of human CYP1 enzymes. In: *Handbook of cannabis and related pathologies*. London: Elsevier, pp. 813–820.
  93. Stout SM and Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. *Drug Metab Rev* 2014; 46: 86–95.
  94. Yamaori S, Okamoto Y, Yamamoto I, *et al.* Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. *Drug Metab Dispos* 2011; 39: 2049–2056.
  95. U.S. Food and Drug Administration. FDA briefing document: peripheral and central nervous system drugs advisory committee meeting (NDA 210365, Cannabidiol), <https://www.fda.gov/media/112565/download> (2018).
  96. Freeman TP, Hindocha C, Green SF, *et al.* Medicinal use of cannabis based products and cannabinoids. *BMJ* 2019; 365: 1–7.
  97. Bonn-Miller MO, Loflin MJE, Thomas BF, *et al.* Labeling accuracy of cannabidiol extracts sold online. *JAMA* 2017; 318: 1708–1709.
  98. Rianprakaisang T, Gerona R and Hendrickson RG. Commercial cannabidiol oil contaminated with the synthetic cannabinoid AB-FUBINACA given to a pediatric patient. *Clin Toxicol*. Epub ahead of print 24 May 2019. DOI: 10.1080/15563650.2019.1619758.
  99. Schonhofen P, Bristot IJ, Crippa JA, *et al.* Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system. *CNS Drugs* 2018; 32: 697–712.
  100. Thomas A, Baillie GL, Phillips AM, *et al.* Cannabidiol displays unexpectedly high potency as an antagonist of CB 1 and CB 2 receptor agonists in vitro. *Br J Pharmacol* 2007; 150: 613–623.
  101. Laprairie RB, Bagher AM, Kelly MEM, *et al.* Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. *Br J Pharmacol* 2015; 172: 4790–4805.
  102. Bisogno T, De Petrocellis L, Mechoulam R, *et al.* Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. *Br J Pharmacol* 2001; 134: 845–852.
  103. Russo EB, Burnett A, Hall B, *et al.* Agonistic properties of cannabidiol at 5-HT<sub>1a</sub> receptors. *Neurochem Res* 2005; 30: 1037–1043.
  104. Ryberg E, Larsson N, Sjögren S, *et al.* The orphan receptor GPR55 is a novel cannabinoid receptor. *Br J Pharmacol* 2007; 152: 1092–1101.
  105. Drysdale AJ, Ryan D, Pertwee RG, *et al.* Cannabidiol-induced intracellular Ca<sup>2+</sup> elevations in hippocampal cells. *Neuropharmacology* 2006; 50: 621–631.
  106. Gururajan A and Malone DT. Does cannabidiol have a role in the treatment of schizophrenia? *Schizophr Res* 2016; 176: 281–290.
  107. Eggen SM and Lewis DA. Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. *Cereb Cortex* 2007; 17: 175–191.
  108. Herkenham M, Lynn A, Johnson M, *et al.* Characterization and localization of cannabinoid

receptors in rat brain: a quantitative in vitro autoradiographic study. *J Neurosci* 1991; 11: 563–583.

109. Glass M, Dragunow M and Faull RLM. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. *Neuroscience* 1997; 77: 299–318.
110. Wong DF, Kuwabara H, Horti AG, *et al.* Quantification of cerebral cannabinoid receptors

subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [<sup>11</sup>C]OMAR. *Neuroimage* 2010; 52: 1505–1513.

111. Bossong M, Jansma M, Bhattacharyya S, *et al.* Role of the endocannabinoid system in brain functions relevant for schizophrenia: an overview of human challenge studies with cannabis or Δ9-tetrahydrocannabinol (THC). *Prog Neuro-Psychopharmacology Biol Psychiatry* 2014; 52: 53–69.

Visit SAGE journals online  
[journals.sagepub.com/  
home/tpp](http://journals.sagepub.com/home/tpp)

 SAGE journals